---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-096035"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:39:05.808275+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Praxis Precision Medicines announces positive topline results from EMBOLD study of relutrigine in SCN2A/SCN8A DEE

## Summary
- Placebo-adjusted reduction of 46% in countable motor seizures for relutrigine-treated patients.
- 5 of 16 randomized patients achieved 28-day seizure-free status on relutrigine vs. none on placebo.
- Relutrigine was generally safe and well tolerated; no patients discontinued due to adverse events.
- Eight patients completed ≥1 OLE period with median motor seizure reduction of 75%.

## SEC filing metadata
- accession: 0001104659-24-096035
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000110465924096035/0001104659-24-096035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000110465924096035/tm2423220d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-096035
- JSON: https://secwatch.observer/filing/0001104659-24-096035.json
- Plain text: https://secwatch.observer/filing/0001104659-24-096035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.